olorofim (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Fungal Infections

Pending FDA approval for treatment of invasive fungal infections in patients who have limited or no treatment options, including aspergilllosis, lomentosporiosis, scedosporiosis, Scopulariopsis infections, and refractory extrapulmonary coccidioidomycosis, or probable pulmonary invasive aspergillosis

Next:

Pharmacology

Mechanism of Action

Selectively inhibits fungal dihydroorotate dehydrogenase (DHODH), a key enzyme in fungal pyrimidine biosynthesis

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.